Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial Business, Chapter 11 Bankruptcy, Clinical Studies, Dermatologicals, Psoriasis, Quarterly results, Shares, T-Cells, Tropomyosin receptor kinase A (TrkA) inhibitors Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent. Read more September 18, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-09-18 12:31:352019-09-18 13:01:33Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial
